Airway inflammation is often associated with bacterial infections and represents a major determinant of lung disease. The in vivo determination of the pro-inflammatory capabilities of various factors is challenging and requires terminal procedures, such as bronchoalveolar lavage and the removal of lungs for in situ analysis, precluding longitudinal visualization in the same mouse. Here, lung inflammation is induced through the intratracheal instillation of Pseudomonas aeruginosa culture supernatant (SN) in transiently transgenized mice expressing the luciferase reporter gene under the control of a heterologous IL-8 bovine promoter. Luciferase expression in the lung is monitored by in vivo bioluminescent image (BLI) analysis over a 2.5-to 48-h timeframe following the instillation. The procedure can be repeated multiple times within 2 -3 months, thus permitting the evaluation of the inflammatory response in the same mice without the need to terminate the animals. This approach permits the monitoring of pro-and anti-inflammatory factors acting in the lung in real time and appears suitable for functional and pharmacological studies.
Introduction
Chronic lung diseases, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and bronchiectasis, are characterized by airway inflammation. Airway inflammation is characterized by edema, cellular infiltration, T lymphocyte and mast cell activation, increased airway secretions, and excessive collagen deposition. CF is a multisystem disorder, and its major cause of mortality and morbidity is lung bacterial infection with increasing pulmonary exacerbation. The decline in lung function predicts a significantly poorer outcome 1, 2, 3, 4 .
The inflammation state of the respiratory tract is usually observed through the evaluation of immunological markers recruited during the inflammatory process in material derived from the lower and upper airways, such as sputum, which provides variable results. Bronchoscopies are also performed 5 . Murine models are valuable tools for investigating the pathogenesis and evolution of diseases characterized by airway inflammation and for which effective treatments or cures have not yet been identified. Animal models of lung infection and inflammation have been used to study asthma and host-pathogen interactions, including the role of chemicals that simulate human conditions (e.g., cigarette smoke exposure, LPS, elastase, ovalbumin, poly I:C, etc., as well as combinations of the above) 6 . The measurement of inflammation-related parameters requires the sacrifice of the animals, as invasive approaches are required to measure factors such as bacterial load, cytokines in the lungs, and collected bronchoalveolar lavage (BAL) fluid. Also, histological examinations are often required. The possibility of obtaining information on the inflammatory response kinetics requires the use of numerous mice. Therefore, a technique that would allow for obtaining such information without the need to sacrifice the animals is valuable on technical, ethical, economical, and operational bases. NOTE: The complexes should be cationic for effective cell entry. The N/P ratio is defined as the number of nitrogen residues (N) on the in vivo delivery reagent per nucleic acid phosphate (P) and represents the measure of the ionic balance within the complexes.
3. Dilute the calculated amount (see step 1.2.1) of nucleic acid in 5% glucose (final concentration) using 10% glucose stock solution (provided) and sterile water. Make sure that the dilution volume is half the final injection volume. Vortex gently or mix by pipetting up and down. 4. Dilute the calculated amount (see step 1.2.3) of delivery reagent into half the injection volume of 5% glucose (final concentration) using the 10% glucose stock solution (provided) and sterile water. Vortex gently and spin at 13,000 x g for 15 s. 5. Add the above diluted delivery reagents to the diluted nucleic acid all at once. Mix them by gentle vortexing and spin down at 13,000 x g for 15 s. 6. Incubate the mixture from step 1.5 for 15 min at room temperature.
NOTE: From this point on, the complexes are stable for 4 h at room temperature and for up to 7 days when stored at 4 °C. 7. Perform tail-vein injections using complexes equilibrated at room temperature. Place the mouse tail into warm water (50 -53 °C) for 30 s to allow for vein dilation. 1. Place the mouse inside the restraining device. Insert a 27-to 30-gauge needle in the tail vein at a 20 -30° angle and slowly inject 200 µL. Upon completion, remove the needle and apply pressure to the injection site. NOTE: A slight bulge in the tail during the injection indicates incorrect positioning. If this occurs, remove the needle and repeat the process proximal to the previous site.
8. Visualize gene expression by performing in vivo BLI (see step 2) at 24 and 48 h after the intravenous injection.
In Vivo BLI
NOTE: Beforehand, prepare a fresh stock solution of 15 mg/mL D-luciferin in DPBS, filter-sterilize it using a 0.22-µm filtering unit, and store it at -20 °C.
1. Place the mice into a clear plexiglass anesthesia chamber. Make sure that the isoflurane chamber is full. When ready to anesthetize the animals, ensure that the pump (left) and chamber (right) switches are on. Turn the isoflurane dial to 2.5% for induction and 2% for maintenance. Animals inside the IVIS chamber are kept under 2.5% isofluorane anesthesia during image acquisition. 2. After the mice are fully anesthetized, inject 10 mL/kg bodyweight of the D-luciferin solution by an intraperitoneal route 15 min before imaging.
NOTE: A kinetic study on D-luciferin should be performed to determine the time of the signal peak after the administration of D-luciferin. 3. Open the in vivo imaging system and prepare the imaging chamber by lining it with a piece of black cardstock (discard upon completion).
Place the nose cones as needed for correct anesthesia (use one cone per mouse). NOTE: The tube that supplies the anesthesia to the instrument is split so that the same concentration of anesthesia is plumbed to the anesthesia manifolds located inside the imaging system. 4. Transfer the mice (up to 5) from the box to the nose cones attached to the manifold in the imaging system and close the door. Image acquisition lasts 5 min. 5. Acquire a BLI using the manufacturer's software, as follows.
1. Initialize the software. In the in vivo imaging system acquisition control panel, put a check mark next to Luminescent. Confirm that the Excitation Filter setting is Block and the Emission Filter setting is Open. 
Discussion
In a previous work 11 , a contrast between bIL-8-Luc-dependent BLI and BAL markers was shown. It relied on the differential degree of sensitivity within mouse strains 12 . For this reason, the first application of the bIL-8-Luc model to a different mouse strain requires an initial study of the inflammatory response, both in terms of BLI and more standardized inflammatory markers.
Mice transfection causes mild lung inflammation and the activation of bIL-8-Luc, which is detectable by BLI up to 3 -4 days after DNA injection (Figure 4) . It then completely disappears after 1 week This approach has been tested on the acute phase of inflammation, but its application to the chronic phase has not been tested. It is not known how the live microorganism challenge could impact the activity of the promoter used in this setting. An increased understanding of the pathogenesis of acute and chronic inflammation and the consequent alteration of lung function is essential for the development of effective therapies for a number of chronic lung diseases 3, 9 . Animal models continue to be necessary for this purpose, although limitations in accurately reflecting human disease pathophysiology are present.
The in vivo monitoring of inflammatory parameters in small rodents using luciferase reporter genes derived from other species is of great value. This approach permits the study of the pathophysiology of inflammatory responses, as well as the ability to test interventions aimed at their modulation. This was successfully tested using a previously well-characterized bovine IL-8 promoter/luciferase transiently transgenized (bovinized) mouse model 1 . Moreover, a recent study 10 demonstrated that the model described here is appropriate for monitoring lung inflammatory response induced by bacterial exoproducts and for investigating the mechanism of action of compound(s) of interest. BLI is a noninvasive approach that allows for the longitudinal observation of the lung inflammatory process after intratracheal instillation with relevant stimuli, including P. aeruginosa culture supernatant 9, 10, 11 . This is an obvious advantage of studying acute lung inflammation compared to classical methods, which require the sacrifice of the animals to collect BAL fluid and the lungs. Its value for the study of chronic infection/inflammation has not been addressed.
The present model can be used to deepen the available knowledge on the pathogenesis of lung inflammatory diseases, including the characterization of bacterial/non-bacterial factors with pro-inflammatory activity. Furthermore, it can facilitate the evaluation of the possible therapeutic effects of molecules with known/presumptive anti-inflammatory actions.
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